Patents by Inventor Hamish Allen

Hamish Allen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IL-1 ALPHA DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF
    Publication number: 20140335014
    Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Application
    Filed: April 8, 2014
    Publication date: November 13, 2014
    Applicant: AbbVie, Inc.
    Inventors: Tariq Ghayur, Peter C. Isakson, Lisa M. Olson, Chengbin Wu, Margaret Hugunin, Rajesh V. Kamath, Carolyn A. Cuff, Hamish Allen
  • Kinase inhibitors as therapeutic agents
    Publication number: 20060074102
    Abstract: A compound or pharmaceutically acceptable salts thereof of Formula (I) wherein the substituents are as defined herein, which are useful as kinase inhibitors.
    Type: Application
    Filed: May 13, 2005
    Publication date: April 6, 2006
    Inventors: Kevin Cusack, Jose-Andres Salmeron-Garcia, Thomas Gordon, Claude Barberis, Hamish Allen, Agniezka Bischoff, Anna Ericsson, Michael Friedman, Dawn George, Gregory Roth, Robert Talanian, Christine Thomas, Grier Wallace, Neil Wishart, Zhengtian Yu
  • Transgenic knockout mouse having functionally disrupted interleukin-1.beta. converting enzyme gene
    Patent number: 6100445
    Abstract: A transgenic mouse having somatic and germ cells in which at least one allele of an endogenous interleukin-1.beta. converting enzyme (ICE) gene is functionally disrupted is provided. The mouse may be heterozygous or, more preferably, homozygous for the ICE gene disruption. In homozygous mice, secretion of mature interleukin-1.beta. and interleukin-1.alpha. is substantially reduced relative to non-mutant mice. The mice of the invention can be used as positive controls to evaluate the efficacy of ICE inhibitors and to identify disease conditions that can be treated with ICE inhibitors. A transgenic mouse having functionally disrupted endogenous ICE genes but which has been reconstituted with a human ICE gene is also provided. This mouse can be used to identify agents that inhibit human ICE in vivo.
    Type: Grant
    Filed: October 20, 1997
    Date of Patent: August 8, 2000
    Assignee: BASF Aktiengesellschaft
    Inventors: Tara Seshadri, Ping Li, Hamish Allen, Subhashis Banerjee, Michael Paskind